What is the current Price Target for the MediClin stock?

The average MediClin target price is €4.70. This is 62.07% higher than the current stock price. The highest price target is 68.97%, the lowest is 55.17%. 2 Analysts have issued a price target MediClin 2026 .

How high will the MediClin stock rise?

No reliable answer can be given as to how high the MediClin stock will rise. The performance of stocks, including the MediClin stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the MediClin stock today?

The performance of MediClin stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the MediClin stock fall?

The decline in MediClin stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

MediClin Forecast, price target & analysts

€2.90

2.03%

Xetra, Thu, Apr 17 2025

ISIN

DE0006595101

Symbol

MED

Index

CDAX

Sector

Health

Industry

Health service provider

Overview Dividends Analysts Charts News Strategies

MediClin Target price 2025 - Analyst rating & recommendation

MediClin Classifications & Recommendation:

Buy

100%

MediClin Price Target

Target Price	€4.70
Price	€2.90
Potential	62.07% register free of charge
Number of Estimates	2

	2 Analysts have issued a price target MediClin 2026 . The average MediClin target price is €4.70. This is 62.07% register free of charge higher than the current stock price. The highest price target is €4.90 68.97% register free of charge , the lowest is €4.50 55.17% register free of charge .
	A rating was issued by 2 analysts: 2 Analysts recommend MediClin to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the MediClin stock has an average upside potential 2026 of 62.07% register free of charge . Most analysts recommend the MediClin stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2029

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Revenue Million €	730.07	748.80
	3.60%	2.57%
EBITDA Margin	8.76%	13.86%
	15.79%	58.23%

1 Analyst has issued a sales forecast MediClin 2024 . The average MediClin sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2023	€730m	3.60%
2024	€749m 2.57% Unlock
2025	€773m 3.23% Unlock
2026	€794m 2.74% Unlock
2027	€818m 3.00% Unlock
2028	€843m 3.06% Unlock
2029	€868m 2.97% Unlock

1 Analyst has issued an EBITDA forecast MediClin 2024 . The average MediClin EBITDA estimate is

Unlock

. This is

Unlock

than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future EBITDA Margins:

2023	€64.0m	12.76%
2024	€104m 62.34% Unlock
2025	€105m 0.77% Unlock
2026	€106m 1.29% Unlock
2027	€111m 5.01% Unlock
2028	€115m 3.00% Unlock
2029	€119m 3.76% Unlock

2023	8.76%	15.79%
2024	13.86% 58.23% Unlock
2025	13.53% 2.38% Unlock
2026	13.34% 1.40% Unlock
2027	13.60% 1.95% Unlock
2028	13.60% 0.00% Unlock
2029	13.70% 0.74% Unlock

Current MediClin Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
SOLVENTIS RESEARCH	Locked ➜ Locked	Locked	Apr 01 2025
SOLVENTIS RESEARCH	Locked ➜ Locked	Locked	Nov 14 2024
DZ BANK	Locked ➜ Locked	Locked	Nov 12 2024

Analyst Rating	Date
Locked SOLVENTIS RESEARCH: Locked ➜ Locked	Apr 01 2025
Locked SOLVENTIS RESEARCH: Locked ➜ Locked	Nov 14 2024
Locked DZ BANK: Locked ➜ Locked	Nov 12 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 59.18%

Infineon 54.07%

Amazon.com 51.90%

Meta Platforms (Facebook) 49.74%

Snowflake 47.61%

Walt Disney 47.00%

Alibaba Group Holding Ltd 46.73%

NIO ADR 46.33%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now